• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Issue Issue 2
Issue Issue 1
Volume Volume 1 (2019)
Allam, A. (2020). STUDY OF SERUM S100P LEVEL AND ITS RELATION TO DIABETIC PERIPHERAL NEUROPATHY IN PATIENTS WITH TYPE 2 DIABETES. ALEXMED ePosters, 2(1), 9-10. doi: 10.21608/alexpo.2020.40413.1012
Aya Ibrahim Ali Mohammed Allam. "STUDY OF SERUM S100P LEVEL AND ITS RELATION TO DIABETIC PERIPHERAL NEUROPATHY IN PATIENTS WITH TYPE 2 DIABETES". ALEXMED ePosters, 2, 1, 2020, 9-10. doi: 10.21608/alexpo.2020.40413.1012
Allam, A. (2020). 'STUDY OF SERUM S100P LEVEL AND ITS RELATION TO DIABETIC PERIPHERAL NEUROPATHY IN PATIENTS WITH TYPE 2 DIABETES', ALEXMED ePosters, 2(1), pp. 9-10. doi: 10.21608/alexpo.2020.40413.1012
Allam, A. STUDY OF SERUM S100P LEVEL AND ITS RELATION TO DIABETIC PERIPHERAL NEUROPATHY IN PATIENTS WITH TYPE 2 DIABETES. ALEXMED ePosters, 2020; 2(1): 9-10. doi: 10.21608/alexpo.2020.40413.1012

STUDY OF SERUM S100P LEVEL AND ITS RELATION TO DIABETIC PERIPHERAL NEUROPATHY IN PATIENTS WITH TYPE 2 DIABETES

Article 2, Volume 2, Issue 1, August 2020, Page 9-10  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2020.40413.1012
View on SCiNiTO View on SCiNiTO
Author
Aya Ibrahim Ali Mohammed Allam email
department of internal medicine, faculty of medicine , Alexandria university, Egypt
Abstract
Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes. DPN is the commonest cause of neuropathy worldwide accounting for about 75% of the diabetic neuropathies. The most critical complications of DPN include foot ulcers, Charcot foot abnormalities, injuries, and eventually, lower-extremity amputation, especially when concomitant peripheral vascular disease causes foot ischemia.
S100P, a 95 amino acid protein, functions as intracellular regulator of diverse cellular processes including protein phosphorylation, cytoskeletal function, and protection from oxidative cell damage. S100P can act in an autocrine manner through binding to receptor for advanced glycation end products (RAGE). RAGE is the main receptor through which AGE signalling, one of the main pathophysiological mechanisms of diabetes and DPN, is mediated. This activation of RAGE by the S100P may be a source of underlying neuropathy in diabetes through their contribution to oxidative stress, activation of caspase-3 and changes induced in the DNA molecules. So, distorted expression of the S100P may be implicated in the pathogenesis of DPN through activation of the advanced glycation end products-RAGE alliance.
Keywords
S100P; type 2 diabetes; peripheral neuropathy
Statistics
Article View: 251
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.